201 related articles for article (PubMed ID: 11151028)
1. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Chazan AC; Gomes MB
Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
[TBL] [Abstract][Full Text] [Related]
2. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
Aschner P; Kattah W
Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
4. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
5. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
[TBL] [Abstract][Full Text] [Related]
6. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
Quatraro A; Consoli G; Ceriello A; Giugliano D
Diabete Metab; 1986 Dec; 12(6):315-8. PubMed ID: 3545931
[TBL] [Abstract][Full Text] [Related]
7. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
8. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Pugh JA; Wagner ML; Sawyer J; Ramirez G; Tuley M; Friedberg SJ
Diabetes Care; 1992 Aug; 15(8):953-9. PubMed ID: 1387073
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Güvener N; Gedik O
Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
12. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
[TBL] [Abstract][Full Text] [Related]
13. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
14. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
15. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
[TBL] [Abstract][Full Text] [Related]
16. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Osei K; Falko JM
Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
[TBL] [Abstract][Full Text] [Related]
17. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Brogard JM; Pinget M; Dorner M
Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
[TBL] [Abstract][Full Text] [Related]
18. Long term improvement in insulin response with gliclazide treatment.
Bodansky HJ; Medback S; Cudworth AG; Rees LH; de Silva RS
Diabete Metab; 1982 Dec; 8(4):319-22. PubMed ID: 6761187
[TBL] [Abstract][Full Text] [Related]
19. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics.
Couturier E
Diabetes Res Clin Pract; 1985-1986 Mar; 1(6):343-7. PubMed ID: 3915271
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
